Live Breaking News & Updates on Nitric Oxide Therapy

Stay updated with breaking news from Nitric oxide therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovations and technology transforming 'Neonatal baby care'

Major advances in neonatal care have helped the sickest and smallest of babies survive ....

Administration Of Surfactant , Extraction Technology , Continuous Positive Airway Pressure , Nitric Oxide Therapy , Pulmonary Hypertension , Extracorporeal Membrane Oxygenation , Signal Extraction , Signal Extraction Technology , Polymerase Chain Reaction , Micro Diagnostic Techniques ,

Claritas Completes Acquisition of Exclusive Worldwide

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease. ....

United States , South Korea , Robert Farrell , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group To Claritas , Salzman Group Inc , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Ltd , Venture Exchange , Salzman Group Pty , Clarita Development Plan , License Amendment , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Clarita President , Positive Data , Validated Animal Model , Disease Progression , Near Total Relief , Acute Symptoms , Potential Cure , Safety Profile ,

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , South Korea , Grand View , Salvador Moncada , Robert Farrell , Pahand Pphnarelethal , Adrianh Chester , Magdih Yacoub , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group To Claritas , View Research , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Inc , Venture Exchange , Regulation Services Provider , Salzman Group Pty , Clarita Development Plan , License Amendment , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Clarita President ,

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS
teletrader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from teletrader.com Daily Mail and Mail on Sunday newspapers.

Sao Paulo , Rio De Janeiro , Estado Do Rio , Robert Farrell , Rezaa Ghiladi , Jun Wang , Jingrui Jiang , Shenghan Lai , Chuan Liu , Sara Akerstrom , Mehrdad Mousavi Jazi , Wanyi Fang , Mikael Leijon , Jonas Klingstrom , Ali Mirazimi , Brazilian Health Regulatory Agency , Claritas Pharmaceuticals Inc , Company Or Claritas , Claritas Pharmaceuticals , Venture Exchange , Regulation Services Provider , Biozeus Biopharmaceuticals , Clinical Study , Clarita President , Induces Expression , Nitric Oxide Synthase ,

Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
Claritas Pharmaceuticals, Inc.April 14, 2021 GMT
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary arterial hypertension (“PAH”). The Company expects that definitive agreements will be executed by May 15, 2021. Closing of the transaction is sub ....

South Australia , United States , South Korea , San Francisco , Salvador Moncada , Robert Farrell , Adrianh Chester , Magdih Yacoub , Company Or Claritas , Claritas Pharmaceuticals , View Research , Salzman Group Inc , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Venture Exchange , Salzman Group Pty , Regulation Services Provider , Clarita Development Plan , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Both Viral Infections , Clarita President , Nitric Oxide ,